Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen L Goode

Showing results (91-100 of 323) with videos related to

Pageof 33
Sort By:
Frontiers in Genetics|March 31, 2012
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian CarcinomaLinda E Kelemen, Qinggang Wang, Irina Dinu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2008
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancerThomas A Sellers, Yifan Huang, Julie Cunningham, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Journal of the National Cancer Institute|November 16, 2006
Age-related lobular involution and risk of breast cancerTia R Milanese, Lynn C Hartmann, Thomas A Sellers, et al.
Molecular Carcinogenesis|April 12, 2011
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer riskEllen L Goode, Kristin L White, Robert A Vierkant, et al.
Oncotarget|October 6, 2015
Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersChristine Mehner, Ann L Oberg, Kimberly R Kalli, et al.
BMC Cancer|June 9, 2009
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancerKristin L White, Robert A Vierkant, Catherine M Phelan, et al.
Journal of the National Cancer Institute|October 2, 2014
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerGottfried E Konecny, Chen Wang, Habib Hamidi, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Pageof 33

Showing results (91-100 of 323) with videos related to

Sort By:
Pageof 33
Frontiers in Genetics|March 31, 2012
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian CarcinomaLinda E Kelemen, Qinggang Wang, Irina Dinu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2008
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancerThomas A Sellers, Yifan Huang, Julie Cunningham, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Journal of the National Cancer Institute|November 16, 2006
Age-related lobular involution and risk of breast cancerTia R Milanese, Lynn C Hartmann, Thomas A Sellers, et al.
Molecular Carcinogenesis|April 12, 2011
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer riskEllen L Goode, Kristin L White, Robert A Vierkant, et al.
Oncotarget|October 6, 2015
Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersChristine Mehner, Ann L Oberg, Kimberly R Kalli, et al.
BMC Cancer|June 9, 2009
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancerKristin L White, Robert A Vierkant, Catherine M Phelan, et al.
Journal of the National Cancer Institute|October 2, 2014
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerGottfried E Konecny, Chen Wang, Habib Hamidi, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Pageof 33